These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 37494758)

  • 21. PENCIL imaging: A novel approach for neuromelanin sensitive MRI in Parkinson's disease.
    Liu P; Wang X; Zhang Y; Huang P; Jin Z; Cheng Z; Chen Y; Xu Q; Ghassaban K; Liu Y; Chen S; He N; Yan F; Haacke EM
    Neuroimage; 2024 May; 291():120588. PubMed ID: 38537765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Spatiotemporal changes in substantia nigra neuromelanin content in Parkinson's disease.
    Biondetti E; Gaurav R; Yahia-Cherif L; Mangone G; Pyatigorskaya N; Valabrègue R; Ewenczyk C; Hutchison M; François C; Arnulf I; Corvol JC; Vidailhet M; Lehéricy S
    Brain; 2020 Sep; 143(9):2757-2770. PubMed ID: 32856056
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnosing Parkinson's disease by combining neuromelanin and iron imaging features using an automated midbrain template approach.
    Jokar M; Jin Z; Huang P; Wang Y; Zhang Y; Li Y; Cheng Z; Liu Y; Tang R; Shi X; Min J; Liu F; Chen S; He N; Haacke EM; Yan F
    Neuroimage; 2023 Feb; 266():119814. PubMed ID: 36528314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson's disease using neuromelanin-sensitive MR imaging.
    Ohtsuka C; Sasaki M; Konno K; Koide M; Kato K; Takahashi J; Takahashi S; Kudo K; Yamashita F; Terayama Y
    Neurosci Lett; 2013 Apr; 541():93-8. PubMed ID: 23428505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NigraNet: An automatic framework to assess nigral neuromelanin content in early Parkinson's disease using convolutional neural network.
    Gaurav R; Valabrègue R; Yahia-Chérif L; Mangone G; Narayanan S; Arnulf I; Vidailhet M; Corvol JC; Lehéricy S
    Neuroimage Clin; 2022; 36():103250. PubMed ID: 36451356
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Locus coeruleus integrity correlates with inhibitory functions of the fronto-subthalamic 'hyperdirect' pathway in Parkinson's disease.
    Xu B; He T; Lu Y; Jia J; Sahakian BJ; Robbins TW; Jin L; Ye Z
    Neuroimage Clin; 2022; 36():103276. PubMed ID: 36510410
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuromelanin in parkinsonian disorders: an update.
    Martin-Bastida A; Pietracupa S; Piccini P
    Int J Neurosci; 2017 Dec; 127(12):1116-1123. PubMed ID: 28460588
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Substantia nigra neuromelanin-MR imaging differentiates essential tremor from Parkinson's disease.
    Reimão S; Pita Lobo P; Neutel D; Guedes LC; Coelho M; Rosa MM; Azevedo P; Ferreira J; Abreu D; Gonçalves N; Nunes RG; Campos J; Ferreira JJ
    Mov Disord; 2015 Jun; 30(7):953-9. PubMed ID: 25758364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuromelanin-sensitive magnetic resonance imaging: Possibilities and promises as an imaging biomarker for Parkinson's disease.
    Yan Y; Zhang M; Ren W; Zheng X; Chang Y
    Eur J Neurosci; 2024 May; 59(10):2616-2627. PubMed ID: 38441250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative Analysis Versus Visual Assessment of Neuromelanin MR Imaging for the Diagnosis of Parkinson's disease.
    Reimão S; Pita Lobo P; Neutel D; Guedes LC; Coelho M; Rosa MM; Ferreira J; Abreu D; Gonçalves N; Morgado C; Nunes RG; Campos J; Ferreira JJ
    J Parkinsons Dis; 2015; 5(3):561-7. PubMed ID: 26406136
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Parkinson's disease related signal change in the nigrosomes 1-5 and the substantia nigra using T2* weighted 7T MRI.
    Schwarz ST; Mougin O; Xing Y; Blazejewska A; Bajaj N; Auer DP; Gowland P
    Neuroimage Clin; 2018; 19():683-689. PubMed ID: 29872633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neurogenic orthostatic hypotension in Parkinson's disease: is there a role for locus coeruleus magnetic resonance imaging?
    Palermo G; Galgani A; Bellini G; Lombardo F; Martini N; Morganti R; Paoli D; De Cori S; Frijia F; Siciliano G; Ceravolo R; Giorgi FS
    J Neural Transm (Vienna); 2024 Feb; 131(2):157-164. PubMed ID: 38032367
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantifying iron deposition within the substantia nigra of Parkinson's disease by quantitative susceptibility mapping.
    An H; Zeng X; Niu T; Li G; Yang J; Zheng L; Zhou W; Liu H; Zhang M; Huang D; Li J
    J Neurol Sci; 2018 Mar; 386():46-52. PubMed ID: 29406966
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Parkinson's disease patient displaying increased neuromelanin-sensitive areas in the substantia nigra after rehabilitation with tDCS: a case report.
    Ishikuro K; Hattori N; Imanishi R; Furuya K; Nakata T; Dougu N; Yamamoto M; Konishi H; Nukui T; Hayashi T; Anada R; Matsuda N; Hirosawa H; Tanaka R; Shibata T; Mori K; Noguchi K; Kuroda S; Nakatsuji Y; Nishijo H
    Neurocase; 2021 Oct; 27(5):407-414. PubMed ID: 34503372
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Substantia nigra neuromelanin magnetic resonance imaging in patients with different subtypes of Parkinson disease.
    Wang L; Yan Y; Zhang L; Liu Y; Luo R; Chang Y
    J Neural Transm (Vienna); 2021 Feb; 128(2):171-179. PubMed ID: 33559725
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessing the Role of Locus Coeruleus Degeneration in Essential Tremor and Parkinson's Disease with Sleep Disorders.
    Liu S; Zhou C; Fang Y; Zhu B; Wu H; Wu C; Guo T; Wu J; Wen J; Qin J; Chen J; Duanmu X; Tan S; Guan X; Xu X; Zhang M; Zhang B; Zhao G; Yan Y
    J Parkinsons Dis; 2024; 14(4):833-842. PubMed ID: 38728202
    [TBL] [Abstract][Full Text] [Related]  

  • 37. T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease.
    Schwarz ST; Rittman T; Gontu V; Morgan PS; Bajaj N; Auer DP
    Mov Disord; 2011 Aug; 26(9):1633-8. PubMed ID: 21491489
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Automated neuromelanin imaging as a diagnostic biomarker for Parkinson's disease.
    Castellanos G; Fernández-Seara MA; Lorenzo-Betancor O; Ortega-Cubero S; Puigvert M; Uranga J; Vidorreta M; Irigoyen J; Lorenzo E; Muñoz-Barrutia A; Ortiz-de-Solorzano C; Pastor P; Pastor MA
    Mov Disord; 2015 Jun; 30(7):945-52. PubMed ID: 25772492
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regional Selectivity of Neuromelanin Changes in the Substantia Nigra in Atypical Parkinsonism.
    Chougar L; Arsovic E; Gaurav R; Biondetti E; Faucher A; Valabrègue R; Pyatigorskaya N; Dupont G; Lejeune FX; Cormier F; Corvol JC; Vidailhet M; Degos B; Grabli D; Lehéricy S
    Mov Disord; 2022 Jun; 37(6):1245-1255. PubMed ID: 35347754
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuromelanin-Sensitive Magnetic Resonance Imaging Changes in the Locus Coeruleus/Subcoeruleus Complex in Patients with Typical and Atypical Parkinsonism.
    Nobileau A; Gaurav R; Chougar L; Faucher A; Valabrègue R; Mangone G; Leu-Semenescu S; Lejeune FX; Corvol JC; Arnulf I; Vidailhet M; Grabli D; Degos B; Lehéricy S
    Mov Disord; 2023 Mar; 38(3):479-484. PubMed ID: 36592065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.